This well-conducted review concluded that culture-guided triple therapy was more effective than standard triple therapy for the first-line treatment of Helicobacter pylori infection. Evidence appeared to support the authors' conclusions, but the limited quality of the included studies and potentially limited applicability (to only two countries) may weaken the strength of this evidence.
Study selection
Randomised controlled trials (RCTs) and quasi-RCTs were eligible for inclusion if they compared culture-guided triple therapy/susceptibility test group with standard therapy for the first-line treatment of Helicobacter pylori (H pylori) infection. Standard triple therapy was described as including a proton-pump inhibitor or ranitidine bismuth citrate plus two antibiotics given for seven to 14 days. Culture-guided triple therapy was described as triple therapy where the antibiotics were selected on the basis of susceptibility testing. Eligible trials had to confirm infection based on urea breath testing and confirm H. pylori eradication at least four weeks after treatment completion. The primary review outcome was the H. pylori eradication rate.
Triple therapy regimens in the primary trials included omeprazole or less commonly bismuth citrate and various combinations of the antibiotics amoxicillin, clarithromycin, metronidazole, and/or tinidazole. Trials included both male and female patients; their mean age ranged from 32 to 58 years. Patients in the susceptibility test group were resistant to different combinations of antibiotics (previously given as quadruple therapy that included the above-mentioned drugs plus furazolidone and levofloxacin). Most trials were conducted in Italy; one trial was set in China.
Two reviewers independently conducted searches and resolved disagreements by consensus.
Assessment of study quality
Two reviewers independently assessed trial quality using methods advised by the Cochrane Handbook. Differences were resolved by consensus. Criteria included randomisation, allocation concealment, blinding, reporting of withdrawals /losses to follow-up, and the number of drop-outs.
Data extraction
Two reviewers extracted or calculated numbers of patients with successful eradication of H. pylori on an intention-totreat and a per-protocol basis. Data were used to calculate risk ratios (RRs) and 95% confidence intervals (CIs).
Methods of synthesis
Pooled risk ratios and 95% confidence intervals were calculated using a fixed-effect model. Heterogeneity was assessed using I 2 .
